This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.
Program Description
The role of human epidermal growth receptor 2 (ERBB2) in treating breast cancer has been widely explored, with several agents currently available in treating tumors expressing ERBB2. In recent years, ERBB2 expression in other tumor types has been explored, specifically in malignancies including gastric, colorectal, and lung cancers. Following this program, learners will develop an understanding of HER2-directed therapies across multiple malignancies and will also be able to identify the role of the pharmacist in managing therapies for patients receiving these agents. Specifically, clinical data will be reviewed, with emphasis on the importance of early adverse effect recognition and management.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 15, 2022
Expiration date: April 15, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Classify the evolution of human epidermal growth receptor 2 (ERBB2) as a biomarker across various malignancies
- Discover treatment paradigm shifts in breast, gastric, lung, and colorectal cancer with the continued investigation of HER2-targeted agents
- Optimize management of patients on anti-HER2 therapies through early adverse effect recognition, patient counseling, and coordination of care
Allison Schepers, PharmD, BCOP
Clinical Pharmacist Specialist, Medical Oncology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Amber Draper, PharmD, BCOP
Clinical Coordinator, Oncology/Hematology
Emory Healthcare
Clinical Pharmacy Specialist
Emory Winship Cancer Institute – GI Oncology Clinic
Atlanta, Georgia
Allison Butts, PharmD, BCOP
Clinical Coordinator, Oncology Pharmacy
UK HealthCare – Markey Cancer Center
Director, PGY2 Oncology Pharmacy Residency
University of Kentucky College of Pharmacy
Lexington, Kentucky
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-163-H01-P. The activity is available for CE credit through April 15, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Allison Butts, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:
Advisory Board: AstraZeneca
Allison Schepers, PharmD, BCOP, and Amber Draper, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Medical reviewer Julia Ziegengeist, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:
Other Support: Presenter of a recorded Medscape CE program supported by an educational grant from Genentech
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms